Prostate-specific antigen (PSA) is used worldwide in the detection and management of prostate cancer. Its discovery revolutionised the care of patients with prostate cancer, but there remains a question of why inter-assay variability exists and how significantly this affects the decision-making process in the care of patients with the disease. We conducted a literature review to evaluate the two areas: inter-assay variability and its relation to clinical practice. Our results show there are internationally recognised standard assays, and the variability of assays are reliant on local/national calibration to a set standard preparation and rely on the measurement of different isoforms of PSA on an equimolar basis. Inter-assay variability exists and can be as high as 8%, which has differing impacts on decision making for diagnostic procedures and treatment modalities depending on the clinical circumstances and PSA level.
BioNanoScience – Springer Journals
Published: Nov 7, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud